In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report), with a price target of $21.00. The company’s shares opened today at $10.98.
According to TipRanks, Pantginis is an analyst with an average return of -6.9% and a 37.27% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Rigel, PDS Biotechnology, and Compass Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nuvectis Pharma with a $21.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $20.92 and a one-year low of $5.31. Currently, Nuvectis Pharma has an average volume of 52.06K.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its pipeline products include NXP800, NXP900.
Read More on NVCT:
